For iguratimod, its international use for over a decade offers significant information on its safety and efficacy, and the addition of the anti-PD1 monoclonal antibody pembrolizumab, a Food and Drug Administration (FDA)-approved therapy for select solid tumors, may further accelerate clinical trial initiation for patients with primary CNS tumors. The gene discussed is PDCD1; the disease is central nervous system neoplasm.